Compare JVA & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | XCUR |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 17.6M |
| IPO Year | 1997 | 2017 |
| Metric | JVA | XCUR |
|---|---|---|
| Price | $4.29 | $2.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 34.1K | 12.3K |
| Earning Date | 06-12-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.48 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $2.62 |
| 52 Week High | $5.62 | $9.50 |
| Indicator | JVA | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 40.57 |
| Support Level | $4.08 | $2.62 |
| Resistance Level | $4.75 | $3.50 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 20.24 | 21.08 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.